Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database
Abstract 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug–drug interactions....
Guardado en:
Autores principales: | Isaac V. Cohen, Tigran Makunts, Ruben Abagyan, Kelan Thomas |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b5fcb5c6d48f493398295aa1b6997412 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Isaac V. Cohen, et al.
Publicado: (2017) -
Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Isaac V. Cohen, et al.
Publicado: (2017) -
Sex-dependent psychoneuroendocrine effects of THC and MDMA in an animal model of adolescent drug consumption.
por: Alvaro Llorente-Berzal, et al.
Publicado: (2013) -
How Postmortem Redistribution of MDMA in Acute Alcohol-MDMA Combined-Use Rats Change under Effects of Alcohol
por: Man Liang, et al.
Publicado: (2017) -
Couple Therapy With MDMA—Proposed Pathways of Action
por: Anne C. Wagner
Publicado: (2021)